View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 28, 2020

Roche begins trial of Actemra plus remdesivir to treat Covid-19

Roche has started a Phase III clinical trial to assess its Actemra/RoActemra in combination with Gilead Sciences' remdesivir to treat hospitalised Covid-19 patients with severe pneumonia.

Roche has started a Phase III clinical trial to assess its Actemra/RoActemra in combination with Gilead Sciences’ remdesivir to treat hospitalised Covid-19 patients with severe pneumonia.

Named REMDACTA, the randomised, double-blind, multi-centre trial will compare the safety and efficacy of the combination to remdesivir plus placebo.

Expected to commence patient enrolment next month, the study is designed to involve about 450 patients worldwide, including in the US, Europe and Canada.

The trial’s primary and secondary endpoints include clinical status, mortality, mechanical ventilation, and intensive care variables. Participants will be followed for 60 days after randomisation.

Roche chief medical officer and Global Product Development head Levi Garraway said: “Based on our current understanding, we believe that combining an antiviral with an immune modulator could potentially be an effective approach to treating patients with severe disease.

“We’re pleased to partner with Gilead to determine whether combining these medicines could potentially help more patients during this pandemic.”

The company is also recruiting patients for a separate Phase III trial of Actemra called COVACTA.

This global, randomised, double-blind, placebo-controlled study is evaluating the safety and efficacy of intravenous formulation of the drug plus standard of care (SOC) in hospitalised adults with severe Covid-19 pneumonia.

The first patient for COVACTA, which is being performed in alliance with the US Food & Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA), was randomised on 3 April.

The study is originally designed to recruit 330 patients but the target has now been increased to 450. Results from COVACTA are expected to be made available in the coming months.

The study’s protocol enables the inclusion of patients being treated with antivirals, including experimental antivirals. Data from the REMDACTA trial are expected to supplement the COVACTA study.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena